Takeda Advances Dual-Therapy Ulcerative Colitis Study, Keeping Entyvio in the GI Spotlight
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The phase 4 study “An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis” tests a new combo in hard-to-treat ulcerative colitis. It aims to see if short-term dual therapy can trigger remission and then be maintained on Takeda’s vedolizumab alone, which could expand use in a competitive inflammatory bowel disease market.
The trial gives adults a mix of vedolizumab, an IV antibody sold as Entyvio, and oral tofacitinib, a JAK inhibitor sold as Xeljanz. The goal is to see if this dual approach helps patients get better quickly and then stay stable on vedolizumab alone, which could support a stronger long-term safety and positioning story for Takeda’s core GI asset.
The study uses a single treatment group, so every participant gets the same regimen rather than being randomized to different arms. There is no blinding, meaning doctors and patients know what is being given, and the main aim is to test how well the treatment works in real patients rather than to compare it head to head with another drug.
All patients receive both drugs for 8 weeks and are checked for improvement, with responders then staying on vedolizumab alone for another 44 weeks. Investors should see this as a real-world style design focused on response and remission rates, durability of effect, and safety patterns that can quickly inform clinical practice and label discussions if the data are strong.
The study was first submitted on 18 October 2023, marking the formal start of regulatory tracking and signaling Takeda’s intention to deepen evidence around Entyvio. While primary and final completion dates have not yet been posted, the last update on 17 March 2026 confirms that the protocol and status are current and that the trial is actively moving forward.
Given follow-up of at least 26 weeks after the last vedolizumab dose, data readouts could come in stages, with early induction results before full maintenance and safety findings. This staggered timing matters for investors, as even preliminary positive signals could influence sentiment and sell-side models ahead of final outcomes.
For Takeda (TAK), success could support higher peak sales for Entyvio by reinforcing its role in more severe ulcerative colitis and in patients cycling off JAK inhibitors. Clear evidence that patients can step down from dual therapy to vedolizumab alone would also strengthen the drug’s long-term safety image, which is important in chronic conditions and for payers.
This study also matters for Pfizer’s Xeljanz franchise and for rivals in the ulcerative colitis space such as AbbVie, Johnson & Johnson, and newer oral agents. If the combo shows strong benefits, it could encourage more structured sequencing strategies and raise the bar for future entrants, while also supporting combination approaches as a theme across inflammatory bowel disease portfolios.
In the near term, the update mainly signals continued R&D investment rather than a direct revenue change, but it adds to the pipeline story that can support Takeda’s valuation during periods of macro pressure. Investors should watch for future interim data or conference abstracts, as meaningful efficacy gains or a clean safety profile could act as catalysts for the stock.
The study remains ongoing and recently updated, and further operational and clinical details are available on the ClinicalTrials portal.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
